Market Place
Sourcing Support
Neurelis Enters $208M Agreement to Monetize Intravail Royalties
14 Nov 2024 //
PR NEWSWIRE
American Regent Introduces Fda-Approved Epinephrine Injection, Usp
29 Oct 2024 //
PR NEWSWIRE
Aquestive Presents Analysis of Anaphylm™ Study at ACAAI 2024
25 Oct 2024 //
GLOBENEWSWIRE
Aquestive Announces Positive Results From OAS Challenge Study
24 Oct 2024 //
GLOBENEWSWIRE
BlinkRx Offers Neffy, The First Needle-Free Epinephrine Treatment
07 Oct 2024 //
BUSINESSWIRE
Renaissance Supports Launch of First Nasal Spray for Anaphylaxis
30 Sep 2024 //
CONTRACT PHARMA
Aquestive Therapeutics Spotlights Epinephrine Delivery Pipeline
27 Sep 2024 //
GLOBENEWSWIRE
GoodRx Announces Lowest Cash Price For Neffy
26 Sep 2024 //
BUSINESSWIRE
ARS Pharma Announces US Availability Of Neffy Nasal Spray
23 Sep 2024 //
GLOBENEWSWIRE
Aquestive Therapeutics To Hold Virtual Investor Day
09 Sep 2024 //
GLOBENEWSWIRE
ARS Launches Pre-Ordering For Needle-Free neffy®
04 Sep 2024 //
GLOBENEWSWIRE
ARS Pharmaceuticals`s Eurneffy (epinephrine) Receives Approval in Europe
22 Aug 2024 //
EMA
ARS Pharma Launches Epinephrine Nasal Spray With High Potential
21 Aug 2024 //
FIERCE PHARMA
Aptar’s nasal unidose system delivers FDA-approved neffy
19 Aug 2024 //
INDIANPHARMAPOST
Aquestive Comments On FDA Approval Of Non-Injection Epinephrine For Anaphylaxis
14 Aug 2024 //
GLOBENEWSWIRE
Insignis Therapeutics Gets FDA Fast Track For IN-001 In Anaphylaxis
13 Aug 2024 //
GLOBENEWSWIRE
FDA Approves First Nasal Spray for Treatment of Anaphylaxis
09 Aug 2024 //
PR NEWSWIRE
ARS Pharmaceuticals Reports Q2 2024 Results And Business Highlights
06 Aug 2024 //
GLOBENEWSWIRE
Aquestive Therapeutics Reports Q2 2024 Results And Business Update
06 Aug 2024 //
GLOBENEWSWIRE
Nasus Pharma`s Nasal Epinephrine Powder Shows 5-Year Stability
06 Aug 2024 //
PR NEWSWIRE
Aquestive Reports Positive Data For Anaphylm Self-Administration Study
25 Jul 2024 //
GLOBENEWSWIRE
De Motu Cordis Expands DPI Partnership with Catalent
24 Jul 2024 //
CONTRACT PHARMA
DMC Plans Next Stage For Inhaled Epinephrine Drug-Device Combo
17 Jul 2024 //
PR NEWSWIRE
Belhaven Study Supports Dry Powder Nasal Epinephrine Delivery Solution
09 Jul 2024 //
ACCESSWIRE
Aquestive eports Positive Data from Anaphylm™ Sublingual Film Study
25 Jun 2024 //
GLOBENEWSWIRE
Enforcement Report - Week of June 5, 2024
05 Jun 2024 //
FDA
Aquestive: Epinephrine Sublingual Film PK/PD Data At Allergy Conference
28 May 2024 //
GLOBENEWSWIRE
ARS Highlights neffy Regulatory Progress, Q1 2024 Financials
09 May 2024 //
GLOBENEWSWIRE
Aquestive Therapeutics Q1 2024 Results and Business Update
06 May 2024 //
GLOBENEWSWIRE
ARS Submits neffy® Response To EMA, Partners With CSL Seqirus
30 Apr 2024 //
GLOBENEWSWIRE
Orexo extends patent protection for its nasal epinephrine powder product OX640
22 Apr 2024 //
INDINPHARMAPOST
Orexo Extends US Patent Protection for Nasal Epinephrine OX640
17 Apr 2024 //
PR NEWSWIRE
Endo sues FDA over its handling of generic Adrenalin approvals
11 Apr 2024 //
ENDPTS
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy®
03 Apr 2024 //
GLOBENEWSWIRE
Transo-Pharm Guarantees Uninterrupted Epinephrine Supply
28 Mar 2024 //
PRESS RELEASE
ARS gears up for neffy US approval
22 Mar 2024 //
PHARMACEUTICAL TECHNOLOGY
Aquestive Therapeutics Announces Pivotal Study for Anaphylm
14 Mar 2024 //
GLOBENEWSWIRE
ARS Pharmaceuticals Reviews Commercial Opportunity at neffy Investor Day
07 Mar 2024 //
GLOBENEWSWIRE
Enforcement Report - Week of February 28, 2024
28 Feb 2024 //
FDA
ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy
20 Feb 2024 //
GLOBENEWSWIRE
Aquestive Therapeutics to Present Anaphylm Sublingual Film Data
15 Feb 2024 //
GLOBENEWSWIRE
ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy
05 Feb 2024 //
GLOBENEWSWIRE
Positive Results from Study for Bryn`s Epinephrine Nasal Spray Published
12 Dec 2023 //
PR NEWSWIRE
Aquestive Doses First Patient in Phase 3 Study Evaluating Pharmacokinetics
05 Dec 2023 //
GLOBENEWSWIRE
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy
09 Nov 2023 //
GLOBENEWSWIRE
Enforcement Report - Week of October 11, 2023
11 Oct 2023 //
FDA
ARS Pharma Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy
06 Oct 2023 //
GLOBENEWSWIRE
Single and Repeat Dose Clinical Study of neffy Published
03 Oct 2023 //
GLOBENEWSWIRE
Aquestive Reaffirms Timeline and Pathway for Anaphylm Sublingual Film
20 Sep 2023 //
GLOBENEWSWIRE
FDA Issues CRL for neffy NDA with Request for Additional Study
20 Sep 2023 //
GLOBENEWSWIRE
Enforcement Report - Week of September 6, 2023
06 Sep 2023 //
FDA
Orexo secures patent protection in the US for OX640, a nasal epinephrine powder
29 Aug 2023 //
PR NEWSWIRE
Enforcement Report - Week of August 9, 2023
09 Aug 2023 //
FDA
Aquestive Therapeutics Announces Positive Pharmacokinetic Data for Anaphylm
27 Jul 2023 //
GLOBENEWSWIRE
Aquestive Reports Results from Studies Evaluating Performance of Anaphylm
31 May 2023 //
GLOBENEWSWIRE
China`s market regulator fines, confiscates revenue APIs for epinephrine
31 May 2023 //
ENDPTS
Bausch Health, Canada Inc. recalls all lots of Emerade epinephrine
05 May 2023 //
HEALTH CANADA
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name
20 Apr 2023 //
GLOBENEWSWIRE
Enforcement Report - Week of April 19, 2023
19 Apr 2023 //
FDA
American Regent introduces FDA-approved Epinephrine Injection, USP
30 Mar 2023 //
PR NEWSWIRE
